Page last updated: 2024-11-04

roxarsone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Roxarsone is an organic arsenic compound used as a feed additive in poultry production to control coccidiosis, a parasitic disease. It acts as an anticoccidial agent, inhibiting the growth and development of coccidia parasites. Roxarsone has been shown to improve weight gain and feed efficiency in poultry. It is also believed to have some growth-promoting effects. However, concerns about its potential toxicity, including its role in arsenic accumulation in poultry products, have led to restrictions and bans on its use in some countries. Roxarsone is synthesized through a multi-step process involving reactions of arsenic compounds with organic molecules. Studies on roxarsone focus on its efficacy as an anticoccidial, its potential toxicity and environmental impact, and the development of alternative feed additives to replace its use.'

Roxarsone: An arsenic derivative which has anticoccidial action and promotes growth in animals. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

roxarsone : An organoarsonic acid where the organyl group is 4-hydroxy-3-nitrophenyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5104
CHEMBL ID1321154
CHEBI ID35817
SCHEMBL ID158026
MeSH IDM0019285

Synonyms (157)

Synonym
MLS002154078
smr001233388
wln: wnr bq e-as-qqo
benzenearsonic acid, 4-hydroxy-3-nitro-
3-nitro-4-hydroxyphenylarsonic acid
nitrophenolarsonic acid
component of 3-nitro-10
(4-hydroxy-3-nitrophenyl)arsonic acid
3-nitro-20
3-nitro-4-hydroxybenzenearsonic acid
nsc-2101
ren-o-sal
3-nitro-10
ristat
arsonic acid, (4-hydroxy-3-nitrophenyl)-
aklomix-3
component of 3-nitro-80
component of 3-nitro-20
4-hydroxy-3-nitrophenylarsonic acid
3-nitro
2-nitro-1-hydroxybenzene-4-arsonic acid
nih 1529
a 19603
121-19-7
component of 3-nitro-50
nsc2101
nci-c56508
4-hydroxy-3-nitrobenzenearsonic acid
3-nitro-50
3n4hpa
3-nitro-80
roxarsone
KBIO1_000500
DIVK1C_000500
CHEBI:35817 ,
roxarsonum
roxarson
SPECTRUM_000942
cas-121-19-7
NCGC00016372-01
BSPBIO_000979
PRESTWICK3_000970
ren o-sal
(4-hydroxy-3-nitro-phenyl)arsonic acid
roxarsone (usp/inn)
IDI1_000500
D05771
BPBIO1_001077
SPECTRUM5_001658
AB00052087
kyselina 4-hydroxy-3-nitrofenylarsonova [czech]
brn 1976533
4-hydroxy-3-nitrobenzolarsonsaeure
4-hydroxy-3-nitrophenyl arsonic acid
nitro acid 100 per cent
roxarsonum [inn-latin]
roxarson [inn-spanish]
nsc 2101
roxarsone [usan:inn:ban]
nitrophenoloarsonic acid
c6h6asno6
ai3-16421
ccris 1661
einecs 204-453-7
hsdb 4296
NCGC00094778-02
NCGC00094778-01
KBIO3_001452
KBIOGR_001015
KBIOSS_001422
KBIO2_006558
KBIO2_001422
KBIO2_003990
PRESTWICK1_000970
SPBIO_002900
SPECTRUM2_000479
SPECTRUM3_000566
NINDS_000500
PRESTWICK0_000970
SPBIO_000618
SPECTRUM4_000498
SPECTRUM1500530
BSPBIO_001952
PRESTWICK2_000970
HMS2092G11
inchi=1/c6h6asno6/c9-6-2-1-4(7(10,11)12)3-5(6)8(13)14/h1-3,9h,(h2,10,11,12)
xmvjitfpvvrmhc-uhfffaoysa-
4-hydroxy-3-nitro-benzenearsonic acid
HMS501I22
H0287
HMS1571A21
HMS1920P10
(3-nitro-4-oxidanyl-phenyl)arsonic acid
A804687
HMS2098A21
NCGC00256417-01
tox21_302842
dtxsid9020956 ,
dtxcid70956
tox21_201465
NCGC00259016-01
nsc-757312
nsc757312
pharmakon1600-01500530
tox21_110402
HMS2234I16
AKOS015960757
CCG-39723
NCGC00016372-03
NCGC00016372-04
NCGC00016372-02
CHEMBL1321154
roxarsone [usan:usp:inn:ban]
4-16-00-01188 (beilstein handbook reference)
arsonic acid, as-(4-hydroxy-3-nitrophenyl)-
unii-h5gu9yql7l
h5gu9yql7l ,
kyselina 4-hydroxy-3-nitrofenylarsonova
FT-0616222
roxarsone [mi]
roxarsone [green book]
roxarsone [usp-rs]
roxarsone [usp impurity]
roxarsone [usan]
roxarsone [usp monograph]
roxarsone [hsdb]
roxarsone [inn]
roxarsone [mart.]
2-nitrophenol-4-arsonic acid
HMS3374C10
SCHEMBL158026
tox21_110402_1
NCGC00016372-07
component of unistat-3 (salt/mix)
component of 3-nitro-80 (salt/mix)
component of 3-nitro-50 (salt/mix)
XMVJITFPVVRMHC-UHFFFAOYSA-N
component of 3-nitro-10 (salt/mix)
2-nitrophenolarsonic acid-(4)
HY-B0936
AB00052087_07
J-004458
mfcd00007112
sr-05000001714
SR-05000001714-3
roxarsone, united states pharmacopeia (usp) reference standard
roxarsone, vetranal(tm), analytical standard
SR-05000001714-1
as-(4-hydroxy-3-nitrophenyl)-arsonic acid
(4-hydroxy-3-nitrophenyl)-arsonic acid
(4-hydroxy-3-nitrobenzene)arsonic acid
roxarsone(usan)
roxarsone, ban, inn, usan
SBI-0051507.P003
Q3049725
DB11458
D90831

Research Excerpts

Overview

Roxarsone (RX) is an arsenic (V) organic compound used to treat parasitic diseases and as an additive for animal fattening. Roxarsone is a phenyl-substituted arsonic acid comprising both arsenate and benzene rings.

ExcerptReferenceRelevance
"Roxarsone (RX) is an arsenic (V) organic compound used to treat parasitic diseases and as an additive for animal fattening."( Interaction between roxarsone, an organic arsenic compound, with humic substances in the soil simulating environmental conditions.
Botero, WG; Figueiredo, IM; Nascimento, ALA; Santos, JCC, 2023
)
1.96
"Roxarsone is a phenyl-substituted arsonic acid comprising both arsenate and benzene rings. "( Mechanistic insights into the enhanced removal of roxsarsone and its metabolites by a sludge-based, biochar supported zerovalent iron nanocomposite: Adsorption and redox transformation.
Huang, C; Huang, H; Lei, M; Li, B; Li, Y; Li, Z; Long, J; Tie, B; Wei, D; Zhou, Y, 2020
)
2
"Roxarsone (ROX) is an organoarsenic feed additive of increasing interest used in the poultry industry. "( Identifying Plant Stress Responses to Roxarsone in Soybean Root Exudates: New Insights from Two-Dimensional Correlation Spectroscopy.
Blaney, L; Fu, QL; Zhou, DM, 2018
)
2.19
"Roxarsone is an organoarsenic feed additive used in livestock and poultry production that is released into the environment, where it poses a risk to human health. "( Tumor-promoting and pro-angiogenic effects of roxarsone via VEGFR2/PLCĪ³/PKC signaling.
Chenlin, Z; Lei, W; Pang, Y; Wang, K; Wang, Y; Zhang, Y, 2018
)
2.18
"Roxarsone is an organoarsenic feed additive that can be metabolised to other higher toxic arsenic (As) species in animal manure such as arsenate, arsenite, monomethylarsonic acid, dimethylarsinic acid, 3-amino-4-hydroxyphenylarsonic acid and other unknown As species. "( Uptake of arsenic species by turnip (Brassica rapa L.) and lettuce (Lactuca sativa L.) treated with roxarsone and its metabolites in chicken manure.
He, ZH; Huang, LX; Li, GL; Li, YF; Yang, BM; Yao, LX; Zhou, CM, 2013
)
2.05
"Roxarsone is an organoarsenic feed additive which can be finally degraded to other higher toxic metabolites after excreted by animal. "( Roxarsone and its metabolites in chicken manure significantly enhance the uptake of As species by vegetables.
Deng, X; He, Z; Huang, L; Li, G; Yang, B; Yao, L; Zhou, C, 2014
)
3.29
"Roxarsone is a feed additive widely used in the broiler and swine industries that has the potential to contaminate the environment, mainly via the use of poultry manure as fertilizer, which results in release of inorganic arsenic to the soil and water. "( Response of microbial communities to roxarsone under different culture conditions.
Fei, Y; Li, Y; Liu, Y; Zhang, Z, 2017
)
2.17
"Roxarsone is a commonly used additive in chicken (Gallus gallus) industry. "( Genome-wide expression analysis of roxarsone-stimulated growth of broiler chickens (Gallus gallus).
Li, C; Li, N; Wang, G; Wang, X; Wu, C, 2011
)
2.09

Effects

Roxarsone has a low absorption rate and is mostly excreted with feces, which could pose a risk to human health through environmental and animal food routes. It has been used extensively in the broiler chicken industry.

ExcerptReferenceRelevance
"Roxarsone has a low absorption rate and is mostly excreted with feces, which could pose a risk to human health through environmental and animal food routes."( The VEGFR2/mTOR/S6K1 pathway involved in the angiogenic effects of roxarsone in vitro and in vivo.
Chen, B; Chen, X; Ding, L; Liu, C; Wang, C; Zhang, M; Zhang, Y; Zhou, Z, 2022
)
1.68
"Roxarsone has a low absorption rate and is mostly excreted with feces, which could pose a risk to human health through environmental and animal food routes."( The VEGFR2/mTOR/S6K1 pathway involved in the angiogenic effects of roxarsone in vitro and in vivo.
Chen, B; Chen, X; Ding, L; Liu, C; Wang, C; Zhang, M; Zhang, Y; Zhou, Z, 2022
)
1.68
"Roxarsone has been extensively used in the feed of animals, which is usually excreted unchanged in the manure and eventually enter into animal wastewater, challenging the biological phosphorus removal processes. "( Biological phosphorus removal inhibition by roxarsone in batch culture systems.
Chen, G; Guo, Q; Hu, Z; Liu, L, 2013
)
2.09
"Roxarsone has been used extensively in the broiler chicken industry. "( Environmental concerns of roxarsone in broiler poultry feed and litter in Maryland, USA.
Fisher, DJ; Staver, KW; Yonkos, LT, 2015
)
2.16

Treatment

ExcerptReferenceRelevance
"Roxarsone treatment had no effect on the guanidine soluble collagen pool."( Effects of roxarsone and monensin on digital flexoral tendons of broiler chickens.
Balog, JM; Chapman, HD; Fitz-Coy, SH; Huff, GR; Huff, WE; Rath, NC, 1998
)
1.41

Toxicity

L-cysteine x HCl x H2O (59%) increased rate and efficiency of gain when added to the basal diet, but depressed performance, increased kidney arsenic concentration, and enhanced mortality. Analysis of fluorescein diacetate (FDA) hydrolysis activity revealed that roxarsone does not exert acute toxic on soil microbes.

ExcerptReferenceRelevance
" These problems arose owing to overdosage, variation in species susceptibility, potentiation of the toxic effects of one substance by the presence of another substance, and particular disease or other on-farm factors."( Investigations of toxicity episodes involving chemotherapeutic agents in Victorian poultry and pigeons.
Barr, DA; Forsyth, WM; Reece, RL; Scott, PC,
)
0.13
" L-cysteine x HCl x H2O (59%) increased rate and efficiency of gain when added to the basal diet, but depressed performance, increased kidney arsenic concentration, and enhanced mortality when added to diets containing toxic levels of roxarsone (200 mg/kg or higher)."( Roxarsone toxicity in the chick as influenced by dietary cysteine and copper and by experimental infection with Eimeria acervulina.
Baker, DH; Czarnecki, GL, 1982
)
1.89
" Analysis of fluorescein diacetate (FDA) hydrolysis activity revealed that roxarsone does not exert acute toxic on soil microbes."( Degradation of roxarsone in a silt loam soil and its toxicity assessment.
Chen, G; Chen, Q; Ke, Z; Liang, T; Liu, L, 2014
)
0.99
" Compared to inorganic arsenic, ROX was less toxic to wheat root elongation."( Phytotoxicity and uptake of roxarsone by wheat (Triticum aestivum L.) seedlings.
Blaney, L; Fu, QL; Zhou, DM, 2016
)
0.73

Bioavailability

ExcerptReferenceRelevance
" However, studies on the bioavailability of Rox in humans are scarce."( Accumulation and Transport of Roxarsone, Arsenobetaine, and Inorganic Arsenic Using the Human Immortalized Caco-2 Cell Line.
Le, XC; Leslie, EM; Liu, Q, 2016
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, the degradation and transformation mechanisms of ROX in paddy soil which determine As bioavailability and uptake by rice are still unclear."( Roxarsone transformation and its impacts on soil enzyme activity in paddy soils: A new insight into water flooding effects.
An, YL; Chen, JH; Cui, JL; Fang, LP; Gan, SC; Guo, PR; Zhao, YP, 2021
)
2.06
" Roxarsone has a low absorption rate and is mostly excreted with feces, which could pose a risk to human health through environmental and animal food routes."( The VEGFR2/mTOR/S6K1 pathway involved in the angiogenic effects of roxarsone in vitro and in vivo.
Chen, B; Chen, X; Ding, L; Liu, C; Wang, C; Zhang, M; Zhang, Y; Zhou, Z, 2022
)
1.87

Dosage Studied

A growth-promoting dosage of Cu (250 mg/kg) increased weight gain by 32% in one experiment. The long-term roxarsone dosing decreased the SBR nitrogen removal by 52%. Arsenic levels in blood, urine, kidneys, and liver were measured in additional animals of each sex dosed with 100 or 400 ppm roXarsone.

ExcerptRelevanceReference
" Arsenic levels in blood, urine, kidneys, and liver of rats were measured in additional animals of each sex dosed with 100 or 400 ppm roxarsone."( Toxic responses in F344 rats and B6C3F1 mice given roxarsone in their diets for up to 13 weeks.
Abdo, KM; Elwell, MR; Montgomery, CA; Prejean, JD; Thompson, MB; Thompson, RB, 1989
)
0.73
" A growth-promoting dosage of Cu (250 mg/kg) increased weight gain by 32% in one experiment but showed no efficacy in alleviating the growth-depression resulting from feeding 400 mg/kg roxarsone."( Toxic effects of supplemental copper and roxarsone when fed alone or in combination to young pigs.
Baker, DH; Edmonds, MS, 1986
)
0.73
"The aim of this study was to determine the dosage and the compounds of arsenic that induce fatty liver in mule ducks and also to investigate their effects on tissue residues."( Oral treatment of mule ducks with arsenicals for inducing fatty liver.
Chen, KL; Chiout, PW, 2001
)
0.31
" In this study, the daily clinical dosage of ENR and daily additive amount of ROX were administrated to Bama pigs."( Effect of enrofloxacin and roxarsone on CYP450s in pig.
Ai, X; Jiang, M; Li, Y; Qiu, J; Thunders, M, 2018
)
0.78
" The long-term roxarsone dosing decreased the SBR nitrogen removal by 52."( Roxarsone exposure jeopardizes nitrogen removal and regulates bacterial community in biological sequential batch reactors.
Chen, G; Li, B; Liu, H; Liu, L; Wang, G; Zhang, W, 2018
)
2.28
" Different parameters like heating temperatures, heat duration, stabilizer type and dosage were optimized for effective removal of TCs and ROX."( Study on the remediation of tetracycline antibiotics and roxarsone contaminated soil.
Xia, Z; Xie, B; Xu, Z; Zhan, L, 2021
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
coccidiostatAn agent useful in the treatment or prevention of coccidiosis in man or animals.
antibacterial drugA drug used to treat or prevent bacterial infections.
agrochemicalAn agrochemical is a substance that is used in agriculture or horticulture.
animal growth promotantSubstances that are administered to farmed animals to improve productivity by promoting weight gain, increasing muscle mass, limiting fat deposition, reducing feed consumption, and reducing waste production.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organoarsonic acidAny organoarsenic compound that is the As-organyl derivative of arsonic acid.
2-nitrophenolsA mononitrophenol that is 2-nitrophenol and its derivatives resulting from substitution of one or more of the hydrogens attached to the benzene ring by a non-nitro group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.25890.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
RAR-related orphan receptor gammaMus musculus (house mouse)Potency8.41270.006038.004119,952.5996AID1159521
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency9.03490.000811.382244.6684AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency6.44180.000221.22318,912.5098AID743035
thioredoxin glutathione reductaseSchistosoma mansoniPotency31.62280.100022.9075100.0000AID485364
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.16340.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency45.98100.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.75410.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency60.69570.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.59770.000229.305416,493.5996AID743069; AID743079
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency12.58930.10009.191631.6228AID1346983
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743065
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency1.25890.65619.452025.1189AID927
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency35.48130.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency3.57210.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency39.81070.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.70790.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency1.25891.584913.004325.1189AID927
TAR DNA-binding protein 43Homo sapiens (human)Potency22.38721.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency10.69100.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
14 kDa phosphohistidine phosphataseHomo sapiens (human)IC50 (µMol)80.00007.90007.90007.9000AID1870205
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (87)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
protein dephosphorylation14 kDa phosphohistidine phosphataseHomo sapiens (human)
actin cytoskeleton organization14 kDa phosphohistidine phosphataseHomo sapiens (human)
peptidyl-histidine dephosphorylation14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of T cell receptor signaling pathway14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of lyase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
lamellipodium organization14 kDa phosphohistidine phosphataseHomo sapiens (human)
positive regulation of cell motility14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of ATP citrate synthase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
calcium channel inhibitor activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
transmembrane transporter binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
actin filament binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
protein histidine phosphatase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasm14 kDa phosphohistidine phosphataseHomo sapiens (human)
cytosol14 kDa phosphohistidine phosphataseHomo sapiens (human)
plasma membrane14 kDa phosphohistidine phosphataseHomo sapiens (human)
nuclear body14 kDa phosphohistidine phosphataseHomo sapiens (human)
leading edge of lamellipodium14 kDa phosphohistidine phosphataseHomo sapiens (human)
extracellular exosome14 kDa phosphohistidine phosphataseHomo sapiens (human)
cytosol14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1870206Competitive inhibition of PHPT1 (unknown origin) assessed as change in Km and Vmax at below 150 uM using DifMUP as substrate by Michaelis-Menten based analysis2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1.
AID1870216Inhibition of LHPP (unknown origin) using pyrophosphate as substrate incubated for 30 mins followed by substrate addition and measured after 30 mins by fluorogenic assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1.
AID1870204Mixed inhibition of PHPT1 (unknown origin) assessed as change in Km and Vmax at above 150 uM using DifMUP as substrate by Michaelis-Menten based analysis2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1870205Inhibition of PHPT1 (unknown origin) using DiFMUP as fluorogenic substrate incubated for 30 mins followed by substrate addition and measured every 60 seconds for 30 mins by fluorogenic assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1.
AID1870210Time dependent inhibition of PHPT1 (unknown origin) at 100 uM using DiFMUP as fluorogenic substrate preincubated for 15 to 120 mins followed by substrate addition and measured for 30 mins by fluorogenic assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (206)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (18.93)18.7374
1990's5 (2.43)18.2507
2000's21 (10.19)29.6817
2010's94 (45.63)24.3611
2020's47 (22.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.33 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index52.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.46%)5.53%
Reviews2 (0.93%)6.00%
Case Studies2 (0.93%)4.05%
Observational0 (0.00%)0.25%
Other211 (97.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]